Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
BRD4 degrader AT1 is a novel, potent and highly selective PROTAC-based BRD4 degrader (Kd = 44 nM for Brd4BD2 in cells) with anticancer activity. Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degradation selectivity remain elusive.
ln Vitro |
BRD4 degrader AT1, which has a Kd of 44 nM for Brd4BD2 in cells, is a highly selective Brd4 degrader. Kd values for mutant Brd4BD2 (QVK), Brd2BD1, Brd2BD2, Brd3BD1, Brd3BD2, Brd4 and Brd2BD1 mutant (KEA) were also observed by BRD4 degrader AT1. These values were 111±14 nM, 94±9 nM, and 35±3 nM, respectively. While having little to no effect on Brd2 and Brd3, the BRD4 degrader AT1 (1-3 μM) significantly reduces Brd4 in both directions [1].
|
---|---|
References |
Molecular Formula |
C48H58CLN9O5S3
|
---|---|
Molecular Weight |
972.6794257164
|
Exact Mass |
971.34
|
Elemental Analysis |
C, 59.27; H, 6.01; Cl, 3.64; N, 12.96; O, 8.22; S, 9.89
|
CAS # |
2098836-45-2
|
PubChem CID |
124201841
|
Appearance |
Off-white to light yellow solid powder
|
LogP |
6.3
|
Hydrogen Bond Donor Count |
4
|
Hydrogen Bond Acceptor Count |
12
|
Rotatable Bond Count |
18
|
Heavy Atom Count |
66
|
Complexity |
1700
|
Defined Atom Stereocenter Count |
4
|
SMILES |
CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NCCCCCCSC(C)(C)[C@@H](C(=O)N4C[C@@H](C[C@H]4C(=O)NCC5=CC=C(C=C5)C6=C(N=CS6)C)O)NC(=O)C)C7=CC=C(C=C7)Cl)C
|
InChi Key |
SQNZDYHMCMIGGV-TZPPCSJFSA-N
|
InChi Code |
InChI=1S/C48H58ClN9O5S3/c1-27-29(3)66-47-40(27)41(33-16-18-35(49)19-17-33)54-37(44-56-55-30(4)58(44)47)23-39(61)50-20-10-8-9-11-21-65-48(6,7)43(53-31(5)59)46(63)57-25-36(60)22-38(57)45(62)51-24-32-12-14-34(15-13-32)42-28(2)52-26-64-42/h12-19,26,36-38,43,60H,8-11,20-25H2,1-7H3,(H,50,61)(H,51,62)(H,53,59)/t36-,37+,38+,43-/m1/s1
|
Chemical Name |
(2S,4R)-1-((R)-2-acetamido-3-((6-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)hexyl)thio)-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
|
Synonyms |
BRD4 degrader AT1; BRD4-degrader-AT1; AT-1; AT1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~102.81 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.17 mg/mL (1.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 11.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.17 mg/mL (1.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 11.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.17 mg/mL (1.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.0281 mL | 5.1404 mL | 10.2809 mL | |
5 mM | 0.2056 mL | 1.0281 mL | 2.0562 mL | |
10 mM | 0.1028 mL | 0.5140 mL | 1.0281 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
The crystal structure of the Brd4BD2:MZ1:VHL-ElonginC-ElonginB complex.Nat Chem Biol.2017 May;13(5):514-521. th> |
---|
Brd4BD2and VHL form a stable, cooperative complex in the presence of MZ1. Schematic model of selective PROTAC-induced target degradation.Nat Chem Biol.2017 May;13(5):514-521. td> |
The molecular basis of MZ1-induced compact complex formation between Brd4BD2and VHL. Structure-guided design and characterization of Brd4-selective degrader AT1.Nat Chem Biol.2017 May;13(5):514-521. td> |